AtriCure (ATRC) Competitors

$29.00 +0.20 (+0.69%)

Closing price 04:00 PM Eastern

Extended Trading

$29.00 0.00 (0.00%)

As of 06:19 PM Eastern

ATRC vs. TFX, ITGR, SMA, ATEC, and IART

Should you buy AtriCure stock or one of its competitors? MarketBeat compares AtriCure with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with AtriCure include Teleflex (TFX), Integer (ITGR), Smartstop Self Storage REIT (SMA), Alphatec (ATEC), and Integra LifeSciences (IART). These companies are all part of the "health care equipment" industry.

How does AtriCure compare to Teleflex?

AtriCure (NASDAQ:ATRC) and Teleflex (NYSE:TFX) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and dividends.

AtriCure presently has a consensus price target of $48.71, suggesting a potential upside of 67.98%. Teleflex has a consensus price target of $144.00, suggesting a potential upside of 6.41%. Given AtriCure's stronger consensus rating and higher probable upside, research analysts plainly believe AtriCure is more favorable than Teleflex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AtriCure	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.82
Teleflex	1 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.22

In the previous week, Teleflex had 11 more articles in the media than AtriCure. MarketBeat recorded 13 mentions for Teleflex and 2 mentions for AtriCure. AtriCure's average media sentiment score of 0.46 beat Teleflex's score of 0.44 indicating that AtriCure is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AtriCure	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Teleflex	4 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

AtriCure has a beta of 1.28, suggesting that its stock price is 28% more volatile than the broader market. Comparatively, Teleflex has a beta of 0.82, suggesting that its stock price is 18% less volatile than the broader market.

AtriCure has higher earnings, but lower revenue than Teleflex. AtriCure is trading at a lower price-to-earnings ratio than Teleflex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AtriCure	$534.53M	2.75	-$11.45M	-$0.10	N/A
Teleflex	$1.99B	3.01	-$905.64M	-$22.80	N/A

AtriCure has a net margin of -0.83% compared to Teleflex's net margin of -35.88%. Teleflex's return on equity of 13.29% beat AtriCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AtriCure	-0.83%	0.29%	0.22%
Teleflex	-35.88%	13.29%	6.55%

99.1% of AtriCure shares are owned by institutional investors. Comparatively, 95.6% of Teleflex shares are owned by institutional investors. 4.0% of AtriCure shares are owned by insiders. Comparatively, 0.7% of Teleflex shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

AtriCure beats Teleflex on 11 of the 17 factors compared between the two stocks.

How does AtriCure compare to Integer?

Integer (NYSE:ITGR) and AtriCure (NASDAQ:ATRC) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, earnings, institutional ownership, profitability, valuation, analyst recommendations, risk and dividends.

Integer has higher revenue and earnings than AtriCure. AtriCure is trading at a lower price-to-earnings ratio than Integer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Integer	$1.86B	1.67	$102.81M	$4.01	22.80
AtriCure	$534.53M	2.75	-$11.45M	-$0.10	N/A

In the previous week, Integer had 3 more articles in the media than AtriCure. MarketBeat recorded 5 mentions for Integer and 2 mentions for AtriCure. AtriCure's average media sentiment score of 0.46 beat Integer's score of 0.18 indicating that AtriCure is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Integer	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
AtriCure	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

99.3% of Integer shares are held by institutional investors. Comparatively, 99.1% of AtriCure shares are held by institutional investors. 1.1% of Integer shares are held by company insiders. Comparatively, 4.0% of AtriCure shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Integer has a beta of 0.67, indicating that its stock price is 33% less volatile than the broader market. Comparatively, AtriCure has a beta of 1.28, indicating that its stock price is 28% more volatile than the broader market.

Integer presently has a consensus target price of $98.29, suggesting a potential upside of 7.50%. AtriCure has a consensus target price of $48.71, suggesting a potential upside of 67.98%. Given AtriCure's stronger consensus rating and higher possible upside, analysts clearly believe AtriCure is more favorable than Integer.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Integer	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.27
AtriCure	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.82

Integer has a net margin of 7.64% compared to AtriCure's net margin of -0.83%. Integer's return on equity of 12.83% beat AtriCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Integer	7.64%	12.83%	6.51%
AtriCure	-0.83%	0.29%	0.22%

Summary

Integer beats AtriCure on 9 of the 17 factors compared between the two stocks.

How does AtriCure compare to Smartstop Self Storage REIT?

Smartstop Self Storage REIT (NYSE:SMA) and AtriCure (NASDAQ:ATRC) are both small-cap health care equipment companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, media sentiment, profitability, dividends, risk and analyst recommendations.

99.1% of AtriCure shares are held by institutional investors. 5.5% of Smartstop Self Storage REIT shares are held by insiders. Comparatively, 4.0% of AtriCure shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Smartstop Self Storage REIT has a net margin of 4.38% compared to AtriCure's net margin of -0.83%. Smartstop Self Storage REIT's return on equity of 1.00% beat AtriCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Smartstop Self Storage REIT	4.38%	1.00%	0.54%
AtriCure	-0.83%	0.29%	0.22%

Smartstop Self Storage REIT has higher earnings, but lower revenue than AtriCure. AtriCure is trading at a lower price-to-earnings ratio than Smartstop Self Storage REIT, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Smartstop Self Storage REIT	$281.14M	6.06	-$1.55M	$0.15	205.21
AtriCure	$534.53M	2.75	-$11.45M	-$0.10	N/A

Smartstop Self Storage REIT currently has a consensus price target of $36.94, suggesting a potential upside of 20.02%. AtriCure has a consensus price target of $48.71, suggesting a potential upside of 67.98%. Given AtriCure's stronger consensus rating and higher probable upside, analysts plainly believe AtriCure is more favorable than Smartstop Self Storage REIT.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Smartstop Self Storage REIT	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.73
AtriCure	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.82

In the previous week, Smartstop Self Storage REIT had 3 more articles in the media than AtriCure. MarketBeat recorded 5 mentions for Smartstop Self Storage REIT and 2 mentions for AtriCure. Smartstop Self Storage REIT's average media sentiment score of 0.52 beat AtriCure's score of 0.46 indicating that Smartstop Self Storage REIT is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Smartstop Self Storage REIT	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AtriCure	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Smartstop Self Storage REIT beats AtriCure on 10 of the 15 factors compared between the two stocks.

How does AtriCure compare to Alphatec?

AtriCure (NASDAQ:ATRC) and Alphatec (NASDAQ:ATEC) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, risk, dividends, media sentiment, valuation and profitability.

In the previous week, Alphatec had 19 more articles in the media than AtriCure. MarketBeat recorded 21 mentions for Alphatec and 2 mentions for AtriCure. AtriCure's average media sentiment score of 0.46 beat Alphatec's score of -0.21 indicating that AtriCure is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AtriCure	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Alphatec	2 Very Positive mention(s)	1 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	3 Very Negative mention(s)	Neutral

AtriCure currently has a consensus price target of $48.71, suggesting a potential upside of 67.98%. Alphatec has a consensus price target of $18.58, suggesting a potential upside of 125.53%. Given Alphatec's higher possible upside, analysts plainly believe Alphatec is more favorable than AtriCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AtriCure	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.82
Alphatec	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

99.1% of AtriCure shares are held by institutional investors. Comparatively, 66.4% of Alphatec shares are held by institutional investors. 4.0% of AtriCure shares are held by insiders. Comparatively, 13.5% of Alphatec shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

AtriCure has a beta of 1.28, meaning that its stock price is 28% more volatile than the broader market. Comparatively, Alphatec has a beta of 0.96, meaning that its stock price is 4% less volatile than the broader market.

AtriCure has a net margin of -0.83% compared to Alphatec's net margin of -15.93%. AtriCure's return on equity of 0.29% beat Alphatec's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AtriCure	-0.83%	0.29%	0.22%
Alphatec	-15.93%	-1,183.84%	-15.83%

AtriCure has higher earnings, but lower revenue than Alphatec. AtriCure is trading at a lower price-to-earnings ratio than Alphatec, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AtriCure	$534.53M	2.75	-$11.45M	-$0.10	N/A
Alphatec	$764.16M	1.66	-$143.36M	-$0.82	N/A

Summary

AtriCure beats Alphatec on 11 of the 17 factors compared between the two stocks.

How does AtriCure compare to Integra LifeSciences?

Integra LifeSciences (NASDAQ:IART) and AtriCure (NASDAQ:ATRC) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends, media sentiment and earnings.

Integra LifeSciences has a beta of 1.08, suggesting that its stock price is 8% more volatile than the broader market. Comparatively, AtriCure has a beta of 1.28, suggesting that its stock price is 28% more volatile than the broader market.

Integra LifeSciences currently has a consensus target price of $12.75, indicating a potential downside of 17.15%. AtriCure has a consensus target price of $48.71, indicating a potential upside of 67.98%. Given AtriCure's stronger consensus rating and higher probable upside, analysts plainly believe AtriCure is more favorable than Integra LifeSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Integra LifeSciences	3 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
AtriCure	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.82

AtriCure has lower revenue, but higher earnings than Integra LifeSciences. AtriCure is trading at a lower price-to-earnings ratio than Integra LifeSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Integra LifeSciences	$1.64B	0.73	-$516.47M	-$6.46	N/A
AtriCure	$534.53M	2.75	-$11.45M	-$0.10	N/A

AtriCure has a net margin of -0.83% compared to Integra LifeSciences' net margin of -30.15%. Integra LifeSciences' return on equity of 17.42% beat AtriCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Integra LifeSciences	-30.15%	17.42%	5.00%
AtriCure	-0.83%	0.29%	0.22%

84.8% of Integra LifeSciences shares are owned by institutional investors. Comparatively, 99.1% of AtriCure shares are owned by institutional investors. 3.8% of Integra LifeSciences shares are owned by insiders. Comparatively, 4.0% of AtriCure shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Integra LifeSciences had 1 more articles in the media than AtriCure. MarketBeat recorded 3 mentions for Integra LifeSciences and 2 mentions for AtriCure. AtriCure's average media sentiment score of 0.46 beat Integra LifeSciences' score of 0.36 indicating that AtriCure is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Integra LifeSciences	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
AtriCure	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

AtriCure beats Integra LifeSciences on 12 of the 17 factors compared between the two stocks.

Get AtriCure News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ATRC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ATRC vs. The Competition

Export

Metric	AtriCure	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.47B	$8.23B	$6.28B	$12.28B
Dividend Yield	N/A	2.53%	2.80%	5.32%
P/E Ratio	-290.00	16.23	20.73	25.19
Price / Sales	2.75	7.68	509.92	61.37
Price / Cash	90.99	16.91	43.09	54.25
Price / Book	2.99	3.99	9.90	6.95
Net Income	-$11.45M	$224.05M	$3.55B	$335.25M
7 Day Performance	9.06%	0.63%	-0.30%	-0.70%
1 Month Performance	0.73%	-1.86%	-2.34%	-0.90%
1 Year Performance	-14.83%	1.29%	30.89%	29.67%

AtriCure Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ATRC AtriCure	3.5202 of 5 stars	$29.00 +0.7%	$48.71 +68.0%	-11.1%	$1.47B	$534.53M	N/A	1,300
TFX Teleflex	3.9875 of 5 stars	$131.50 +0.8%	$144.00 +9.5%	+3.8%	$5.82B	$1.99B	N/A	15,500	Dividend Announcement
ITGR Integer	2.1332 of 5 stars	$90.15 +0.2%	$98.29 +9.0%	-25.6%	$3.06B	$1.85B	22.48	11,000
SMA Smartstop Self Storage REIT	3.6603 of 5 stars	$29.65 -0.9%	$36.94 +24.6%	-19.8%	$1.65B	$281.14M	198.57	N/A
ATEC Alphatec	3.6681 of 5 stars	$8.24 +1.8%	$18.58 +125.7%	-36.9%	$1.26B	$764.16M	N/A	700

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ATRC) was last updated on 5/20/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AtriCure (ATRC) Competitors